Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.46 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.45 |
| ▸ | FFAR2 | O15552 | 2/20 | 0.45 |
| ▸ | GCK | P35557 | 3/20 | 0.44 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.43 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | GLS | O94925 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22077754 | 1.00 | POLB (0.47) | POLBMEN1KMT2AHDAC1HDAC3 | |
| SCHEMBL22111715 | 1.00 | POLB (0.47) | POLBMEN1KMT2AHDAC1HDAC3 | |
| SCHEMBL2019875 | 0.90 | FFAR2 (0.55) | POLBMEN1KMT2AKCNQ2FFAR2 | |
| SCHEMBL2019259 | 0.87 | HDAC1 (0.48) | POLBHDAC1HDAC3HDAC4HDAC8 | |
| SCHEMBL2019870 | 0.87 | GLS (0.52) | POLBMEN1KMT2AHDAC1HDAC3 | |
| SCHEMBL2021190 | 0.87 | POLB (0.50) | POLBMEN1KMT2AKCNQ2FFAR2 | |
| SCHEMBL22095552 | 0.87 | POLB (0.50) | POLBMEN1KMT2AKCNQ2FFAR2 | |
| SCHEMBL2015269 | 0.86 | HDAC1 (0.50) | POLBHDAC1HDAC3HDAC4HDAC8 | |
| SCHEMBL2016410 | 0.86 | HDAC1 (0.61) | POLBMEN1KMT2AHDAC1HDAC3 | |
| SCHEMBL2020130 | 0.84 | HDAC1 (0.54) | POLBMEN1KMT2AHDAC1HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402884-A1 | (S)-N-HYDROXY-2-(2-(4-METHOXYPHENYL)BUTANAMIDO)THIAZOLE-5-CARBOXAMIDE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | TRANSLATIONAL DRUG DEVELOPMENT, LLC | 2022-12-22 | — | — | US | claimed |
| US-11420947-B2 | (S)-n-hydroxy-2-(2-(4-methoxyphenyl)butanamido)thiazole-5-carboxamide and pharmaceutically acceptable salts thereof | TRANSLATIONAL DRUG DEVELOPMENT, LLC (US) | 2022-08-23 | — | — | US | claimed |
| US-20220184040-A1 | METHOD OF TREATING MALIGNANT RHABDOID TUMOR OF THE OVARY AND SMALL CELL CANCER OF THE OVARY OF THE HYPERCALCEMIC TYPE | TRANSLATIONAL DRUG DEVELOPMENT, LLC | 2022-06-16 | — | — | US | claimed |
| EP-3946326-A1 | METHOD OF TREATING MALIGNANT RHABDOID TUMOR OF THE OVARY AND SMALL CELL CANCER OF THE OVARY OF THE HYPERCALCEMIC TYPE | TRANSLATIONAL DRUG DEVELOPMENT LLC (US) | 2022-02-09 | — | — | EP | claimed |
| CN-113874013-A | Method for treating malignant rhabdoid tumor of ovary and ovarian small cell carcinoma with hypercalcemia | 转化药物开发有限责任公司 | 2021-12-31 | — | — | CN | claimed |
| US-20210347747-A1 | (S)-N-HYDROXY-2-(2-(4-METHOXYPHENYL)BUTANAMIDO)THIAZOLE-5-CARBOXAMIDE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | TRANSLATIONAL DRUG DEVELOPMENT, LLC | 2021-11-11 | — | — | US | claimed |
| CN-113631158-A | (S) -N-hydroxy-2- (2- (4-methoxyphenyl) butanamido) thiazole-5-carboxamide and pharmaceutically acceptable salts thereof | 转化药物开发有限责任公司 | 2021-11-09 | — | — | CN | claimed |
| EP-3893863-A1 | <SMALLCAPS/>? ? ?S? ? ? ? ?()-N-HYDROXY-2-(2-(4-METHOXYPHENYL)BUTANAMIDO)THIAZOLE-5-CARBOXAMIDE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | TRANSLATIONAL DRUG DEVELOPMENT LLC (US) | 2021-10-20 | — | — | EP | claimed |
| WO-2020198401-A1 | METHOD OF TREATING MALIGNANT RHABDOID TUMOR OF THE OVARY AND SMALL CELL CANCER OF THE OVARY OF THE HYPERCALCEMIC TYPE | TRANSLATIONAL DRUG DEVELOPMENT, LLC (US) | 2020-10-01 | — | — | WO | claimed |
| WO-2020123414-A1 | (S)-N-HYDROXY-2-(2-(4-METHOXYPHENYL)BUTANAMIDO)THIAZOLE-5-CARBOXAMIDE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | TRANSLATIONAL DRUG DEVELOPMENT, LLC (US) | 2020-06-18 | — | — | WO | claimed |
| US-9221773-B2 | Benzamide derivatives | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2015-12-29 | — | — | US | claimed |
| US-20130045982-A1 | BENZAMIDE DERIVATIVES | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2013-02-21 | — | — | US | claimed |
| WO-2011079036-A1 | BENZAMIDE DERIVATIVES | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2011-06-30 | — | — | WO | claimed |
| US-20220402884-A1 | (S)-N-HYDROXY-2-(2-(4-METHOXYPHENYL)BUTANAMIDO)THIAZOLE-5-CARBOXAMIDE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | TRANSLATIONAL DRUG DEVELOPMENT, LLC | 2022-12-22 | — | — | US | disclosed |
| US-20220402884-A1 | (S)-N-HYDROXY-2-(2-(4-METHOXYPHENYL)BUTANAMIDO)THIAZOLE-5-CARBOXAMIDE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | TRANSLATIONAL DRUG DEVELOPMENT, LLC | 2022-12-22 | — | — | US | disclosed |
| US-20220402884-A1 | (S)-N-HYDROXY-2-(2-(4-METHOXYPHENYL)BUTANAMIDO)THIAZOLE-5-CARBOXAMIDE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | TRANSLATIONAL DRUG DEVELOPMENT, LLC | 2022-12-22 | — | — | US | disclosed |
| US-9221773-B2 | Benzamide derivatives | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2015-12-29 | — | — | US | disclosed |
| US-20130045982-A1 | BENZAMIDE DERIVATIVES | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2013-02-21 | — | — | US | disclosed |
| US-20130045982-A1 | BENZAMIDE DERIVATIVES | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2013-02-21 | — | — | US | disclosed |
| WO-2011079036-A1 | BENZAMIDE DERIVATIVES | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220184040-A1 | METHOD OF TREATING MALIGNANT RHABDOID TUMOR OF THE OVARY AND SMALL CELL CANCER OF THE OVARY OF THE HYPERCALCEMIC TYPE | CRAT, SHMT2, BRDT | POLB 4364/4885MEN1 397/4885KMT2A 83/4885 |
| US-20220402884-A1 | (S)-N-HYDROXY-2-(2-(4-METHOXYPHENYL)BUTANAMIDO)THIAZOLE-5-CARBOXAMIDE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | HDAC5, HDAC2, HDAC3 | POLB 2734/4885MEN1 4426/4885KMT2A 45/4885 |
| US-11420947-B2 | (S)-n-hydroxy-2-(2-(4-methoxyphenyl)butanamido)thiazole-5-carboxamide and pharmaceutically acceptable salts thereof | HDAC5, HDAC2, HDAC3 | POLB 2734/4885MEN1 4426/4885KMT2A 45/4885 |
| US-20130045982-A1 | BENZAMIDE DERIVATIVES | BAD, BAK1, BRDT | POLB 295/4885MEN1 3145/4885KMT2A 1317/4885 |
| US-20210347747-A1 | (S)-N-HYDROXY-2-(2-(4-METHOXYPHENYL)BUTANAMIDO)THIAZOLE-5-CARBOXAMIDE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | HDAC5, HDAC2, HDAC3 | POLB 2734/4885MEN1 4426/4885KMT2A 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.